Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 18/20 | 0.56 |
| ▸ | CASP7 | P55210 | 2/20 | 0.55 |
| ▸ | CASP9 | P55211 | 2/20 | 0.55 |
| ▸ | CASP6 | P55212 | 2/20 | 0.55 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24213871 | 1.00 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL17494194 | 1.00 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL29384302 | 0.96 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL26071633 | 0.96 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL4466395 | 0.96 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL20257211 | 0.93 | REN (0.55) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL29825423 | 0.93 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL24310885 | 0.92 | REN (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL15012737 | 0.92 | REN (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL24310886 | 0.92 | REN (0.56) | CASP3CASP7CASP9CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106796219-B | Stabilization of whole blood samples | 通用医疗公司 | 2022-05-27 | — | — | CN | claimed |
| US-10750739-B2 | Stabilization of whole blood samples | THE GENERAL HOSPITAL CORPORATION (US) | 2020-08-25 | — | — | US | claimed |
| CN-113521286-B | Coronavirus protease inhibitors and uses thereof | 中国医学科学院基础医学研究所 | 2023-08-18 | — | — | CN | disclosed |
| CN-106796219-B | Stabilization of whole blood samples | 通用医疗公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-113521286-A | Coronavirus protease inhibitor and application thereof | 中国医学科学院基础医学研究所 | 2021-10-22 | — | — | CN | disclosed |
| US-9707272-B2 | Method for the treatment of acne by administering IL-1β antibody | UNIVERSITAT ZURICH (CH) | 2017-07-18 | — | — | US | disclosed |
| US-20140199320-A1 | MODULATORS OF THE NLRP3 INFLAMMASOME IL-1BETA PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE | UNIVERSITAT ZURICH (CH) | 2014-07-17 | — | — | US | disclosed |
| WO-2013007763-A1 | MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE | Universität Zürich (CH) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140199320-A1 | MODULATORS OF THE NLRP3 INFLAMMASOME IL-1BETA PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE | IL1RN, CASP1, IL1R1 | CASP3 169/4885CASP7 153/4885CASP9 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.